Executive Summary
Dupilumab-like activity in a pill - first oral STAT6 degrader
KT-621
STAT6 · Heterobifunctional degrader
Target: STAT6
Full NameSignal Transducer and Activator of Transcription 6
PathwayIL-4/IL-13 → Type 2 inflammation
Mechanism of Action[Corp '26 S56]
TypeHeterobifunctional degrader (PROTAC)
DescriptionKT-621 is a bifunctional molecule with one end that binds STAT6 and another end that recruits the Cereblon E3 ligase. This brings STAT6 to the cell's protein disposal system (proteasome), which destroys it. One KT-621 molecule can catalytically destroy many STAT6 proteins.
Why This ApproachTPD allows elimination of entire protein, achieving complete pathway blockade equivalent to biologics
DifferentiationUnlike traditional inhibitors (stoichiometric, need continuous high exposure), degraders work catalytically - low/short drug exposures achieve sustained target elimination
Indications:[Corp '26 S15] Atopic DermatitisAsthmaCOPDEosinophilic Esophagitis (EoE)Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)Chronic Spontaneous Urticaria (CSU)Prurigo Nodularis (PN)Bullous Pemphigoid (BP)
Target Biology[Corp '26 S14]
STAT6 is THE transcription factor for IL-4/IL-13 signaling. When IL-4 or IL-13 binds to receptors on cells, STAT6 gets activated, moves to the nucleus, and turns on all the genes that cause allergic inflammation.
Human Genetic Evidence: GoF: STAT6 GoF mutations cause hyper-IgE syndrome and severe allergic disease
LoF: STAT6 heterozygous LoF alleles protect against allergic disease
LoF: STAT6 heterozygous LoF alleles protect against allergic disease
Why Previous Approaches FailedTPD allows elimination of entire protein, achieving complete pathway blockade equivalent to biologics
Clinical Data
Phase 1 SAD/MAD
Phase 1 Completed n=118 (48 SAD, 70 MAD)STAT6 Degradation by Dose[Corp '26 S22]
| Dose | Blood Change | Skin Change | N |
|---|---|---|---|
| Placebo | ~0% | ~0% | 18 |
| 1.5mg QD | ~-20% | ~-10% | 9 |
| 12.5mg QD | ~-70% | ~-60% | 7 |
| 25mg QD | >-90% | >-90% | 9 |
| 50mg QD | >-90% | >-90% | 9 |
| 100mg QD | >-90% | >-90% | 9 |
| 200mg QD | >-90% | >-90% | 9 |
Values approximated from presentation visuals. Official: >90% mean STAT6 degradation at doses ≥25mg; complete degradation at ≥50mg MAD.
Key Findings:
- Clear dose-response from 1.5mg to 25mg
- Plateau at ≥25mg - maximal degradation achieved
- Skin penetration confirmed - critical for dermatology indication
- 100mg vs 200mg equivalent - suggests 100mg sufficient
Safety Profile[Corp '26 S57]
Well-tolerated across all doses; safety profile undifferentiated from placebo
- No SAEs
- No Severe AEs
- No dose-dependent pattern in TEAEs
- No TRAE reported in >1 participant
- No discontinuations due to AEs
- No clinically relevant changes in vitals, labs, ECGs
BroADen Phase 1b
Phase 1b Completed n=22Study Limitations:
- Open-label - no placebo arm
- AD has 25-35% placebo response rate
- Small sample size (n=22)
- Short duration (29 days vs 16 weeks for registration)
- Cross-trial comparison to Dupixent has caveats
Baseline Characteristics[Corp '26 S58-59]
| Age Mean | 31.7 |
| Female % | 59.1 |
| BMI Mean | 31.7 |
| Race White % | 31.8 |
| Race Black % | 54.5 |
| vIGA Moderate % | 54.5 |
| vIGA Severe % | 45.5 |
| EASI Mean | 24.9 |
| PPNRS Mean | 7.5 |
| SCORAD Mean | 60.1 |
| BSA Mean % | 29.6 |
| Comorbid Asthma % | 18.2 |
| Comorbid Allergic Rhinitis % | 40.9 |
| Prior Systemic Therapy % | 22.7 |
| Prior Therapy Detail | ~23% prior biologics (dupilumab and/or tralokinumab) |
| Comorbid Combined % | ~46% comorbid asthma or allergic rhinitis |
| Dose Groups Balanced | Generally well-balanced for gender, age, race, vIGA-AD, EASI, PP-NRS |
Note: 45.5% severe patients and prior biologic use shows this is a sick, treatment-experienced population
Efficacy Endpoints
| Endpoint | Result | vs Comparator |
|---|---|---|
|
STAT6 Degradation[Corp '26 S25]
Target protein elimination in blood and skin
|
98% in blood, 94% in skin at Day 29 | vs Dupilumab: Dupilumab does not degrade STAT6 (different mechanism) |
|
Eczema Area and Severity Index[Corp '26 S28]
Composite of affected BSA × severity (erythema, induration, excoriation, lichenification) across 4 body regions
|
-63% | vs Dupilumab: -52% |
|
Validated Investigator Global Assessment for AD[Corp '26 S33]
Physician assessment of overall disease severity
|
19% | vs Dupilumab: 12% |
|
Peak Pruritus Numerical Rating Scale[Corp '26 S29]
Patient-reported worst itch in past 24 hours
|
-40% | vs Dupilumab: -33% |
|
SCORing Atopic Dermatitis[Corp '26 S28-30]
|
vs Dupilumab: -41% | |
|
Body Surface Area affected[Corp '26 S33]
|
-49% | vs Dupilumab: -36% |
|
Patient-Oriented Eczema Measure[Corp '26 S30]
Patient-reported disease severity and experience
|
73% | vs Dupilumab: 69% |
|
Dermatology Life Quality Index[Corp '26 S30]
Quality of life impact
|
61% | vs Dupilumab: 69% |
Head-to-Head Comparison: KT-621 vs Dupilumab[Corp '26 S33]
Cross-trial comparison - no head-to-head conducted
| Endpoint | KT-621 Day 29 | Dupilumab Day 28 | Winner |
|---|---|---|---|
| Mean % Change EASI | -63% | -52% | KT-621 |
| EASI-50 | 76% | 57% | KT-621 |
| EASI-75 | 29% | 28% | Tie |
| Mean % Change PP-NRS | -40% | -33% | KT-621 |
| Mean % Change SCORAD | -48% | -41% | KT-621 |
| vIGA-AD 0/1 | 19% | 12% | KT-621 |
| Mean % Change BSA | -49% | -36% | KT-621 |
Note: Cross-trial comparisons may not be reliable. No head-to-head trials have been conducted. Data may not be directly comparable due to differences in trial protocols, dosing regimens, and patient populations.
Biomarker Results[Corp '26 S26]
| Biomarker | Result | vs Dupilumab | Interpretation |
|---|---|---|---|
|
TARC (CCL17)
Validated Type 2 marker; T cell chemotaxis
|
-74% median (patients with baseline TARC ≥1,600 pg/mL) | Dupilumab: -74% | Matches Dupilumab exactly - key validation |
|
Eotaxin-3 (CCL26)
Eosinophil chemotaxis; highly specific to IL-4/13
|
-73% | Dupilumab: -51% (in asthma) | BEATS Dupilumab (though different populations) |
|
IgE
Allergic antibody; B cell class switching
|
-14% | Dupilumab: ~15% | Similar to Dupilumab |
|
IL-31
Pruritogenic (itch) cytokine
|
-54% | Dupilumab: Not measured | Explains itch improvement - IL-31 is the 'itch cytokine' |
|
FeNO
Fractional exhaled NO; airway Type 2 inflammation
|
-33% | Dupilumab: Not measured in AD | Suggests potential asthma efficacy |
Skin Transcriptomics[Corp '26 S27]: Significant downregulation from Day 1 to Day 29
(Objective molecular evidence of disease modification at tissue level)
Comorbid Asthma Subgroup (n=4)[Corp '26 S31]
| Measure | Result | vs Dupilumab | Interpretation |
|---|---|---|---|
| Fractional Exhaled Nitric Oxide | -56% median at Day 29 | -31% at Week 4 | KT-621 BEATS Dupilumab on this biomarker |
| Asthma Control Questionnaire | -1.2 points | All patients had clinically meaningful improvement |
Only 4 patients - directionally positive but small n
Comorbid Allergic Rhinitis Subgroup[Corp '26 S32]
| Measure | N | Change | Response |
|---|---|---|---|
| Total Nasal Symptom Score MCID: 0.55 points | n=7 | -0.9 points | 57% responders |
| Rhinoconjunctivitis Quality of Life Questionnaire MCID: 0.5 points | n=6 | -0.8 points | 33% responders |
Safety Profile[Corp '26 S34]
Well-tolerated with favorable safety at both doses; profile similar to Phase 1 HV
- No SAEs
- No Severe AEs
- No dose-dependent pattern in TEAEs
- No related TEAEs leading to discontinuation
- No conjunctivitis (or any ocular disorder) - KEY vs Dupixent
- No herpes infections
- No arthralgias
- No clinically relevant changes in vitals, labs, ECGs
Conjunctivitis: KT-621 0% vs Dupilumab 10-25%
Potential safety differentiation - conjunctivitis limits Dupixent use in some patients
Potential safety differentiation - conjunctivitis limits Dupixent use in some patients
BROADEN2[Corp '26 S19]
Phase 2b Ongoing, also including adolescents Target n=~200 patientsSuccess Criteria:
- easi75_target: ≥40%
- placebo_delta_target: ≥15%
- safety: Maintain clean profile
Failure Criteria:
- easi75_below: <30%
- small_placebo_delta: <10%
- safety_signal: Emergence of conjunctivitis or other concerning AEs
BREADTH[Corp '26 S20]
Phase 2b First patient dosed January 29, 2026. Enrollment ongoing. Target n=~264 patientsInvestment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Bull Case
| Thesis Point | Supporting Evidence | Confidence |
|---|---|---|
| Phase 1b efficacy matches Dupilumab[Corp '26 S33] | EASI -63% vs -52%; EASI-75 29% vs 28%; TARC -74% = -74% | High - Multiple Endpoints Consistent |
| Oral convenience could transform market[Corp '26 S6] | >90% of biologic patients prefer oral; only 1% penetration today | High - Survey Data + Low Penetration |
| Clean safety with no conjunctivitis[Corp '26 S34] | 0% vs 10-25% for Dupixent | Medium - Need Larger N To Confirm |
| No plateau at Day 29 - efficacy may improve[Corp '26 S28] | EASI curve still declining; Dupixent improves through Week 16 | Medium - Need Longer Data |
| Biomarker data is objective validation[Corp '26 S25] | 98% STAT6 degradation in blood, 94% in skin cannot be placebo effect | High - Objective Measurement |
Bear Case
| Risk | Evidence | Mitigating Factors |
|---|---|---|
| Open-label design - placebo effect possible | AD has 25-35% placebo response; no control arm | Biomarker data (STAT6, TARC) is objective and matches Dupilumab (Probability: 30%) |
| Only 29 days of treatment - durability unknown | Dupilumab trials were 16 weeks; long-term efficacy not proven | No plateau at Day 29 suggests continued improvement; some durability at Day 43 off treatment (Probability: 25%) |
| Small sample size | n=22 is underpowered to detect safety signals or subgroup effects | Phase 2b will have ~200 patients (Probability: 20%) |
| Competitive response from Dupixent | Sanofi/Regeneron have resources to defend $13B franchise | Hard to make Dupixent oral; degrader is novel mechanism (Probability: Ongoing risk) |
Key Debates
| Question | Bull View | Bear View | Resolution Catalyst |
|---|---|---|---|
| Can an oral degrader match an injectable biologic? | Yes - 90%+ degradation = complete pathway blockade | No - tissue distribution and half-life may differ | BROADEN2 EASI-75 at Week 16 vs placebo |
| Is the no-conjunctivitis signal real and differentiated? | Yes - mechanistic (STAT6 downstream of IL-4R); 0% vs 10-25% | No - too few patients; could emerge in larger trials | Phase 2b safety data with larger n |
| Will efficacy plateau or continue improving? | Continue - no plateau at Day 29; Dupixent improves through Week 16 | Plateau - mechanism may have ceiling effect | BROADEN2 Week 16 time course data |
Probability of Success
| Phase 2b → Phase 3 | 55% |
| Phase 3 → Approval | 65% |
| Cumulative PoS | 36% |
Historical Phase 2→3 success rates in dermatology + adjustment for strong biomarker data
Market Opportunity[Corp '26 S13]
Total Addressable Market
>$27B by 2030
Current Penetration
Only ~1% of patients on advanced systemic therapy
Oral Preference
>90% of biologic patients would switch to oral option
Competitive Advantage
Oral convenience could expand market penetration from 1% to 10%+
Peak Sales (Bull)
$5B+
Peak Sales (Base)
$3B
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| BROADEN2 Phase 2b AD enrollment completion | 2026 | Medium | Enrollment pace; any protocol amendments | — |
| BROADEN2 Phase 2b AD data | Mid-2027 | Critical | EASI-75 at Week 16 (target ≥40%); Placebo delta (target ≥15%); vIGA-AD 0/1 response rate; Safety - especially conjunctivitis incidence; Dose response - which dose selected for Phase 3 | EASI-75 ~40%; modest beat may be priced in |
| BREADTH Phase 2b Asthma data | Late 2027 | High | FEV1 improvement vs placebo; FeNO reduction; ACQ-5 response; Any exacerbation signal | — |